Back

Optimisation and validation of a sensitive bioanalytical method for niclosamide.

Arshad, U.; Pertinez, H.; Box, H.; Tatham, L.; Rajoli, R.; Neary, M.; Sharp, J.; Valentijn, A.; Hobson, J.; Unsworth, C.; Dwyer, A.; Savage, A.; McDonald, T.; Rannard, S.; Curley, P.; Owen, A.

2021-01-15 pharmacology and toxicology
10.1101/2021.01.13.426426 bioRxiv
Show abstract

The SARS-CoV-2 pandemic has spread at an unprecedented rate, and repurposing opportunities have been intensively studied with only limited success to date. If successful, repurposing will allow interventions to become more rapidly available than development of new chemical entities. Niclosamide has been proposed as a candidate for repurposing for SARS-CoV-2 based upon the observation that it is amongst the most potent antiviral molecules evaluated in vitro. To investigate the pharmacokinetics of niclosamide, reliable, reproducible and sensitive bioanalytical assays are required. Here, a liquid chromatography tandem mass spectrometry assay is presented which was linear from 31.25-2000 ng/mL (high dynamic range) and 0.78-100 ng/mL (low dynamic range). Accuracy and precision ranged between 97.2% and 112.5%, 100.4% and 110.0%, respectively. The presented assay should have utility in preclinical evaluation of the exposure-response relationship and may be adapted for later evaluation of niclosamide in clinical trials.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.